Pathogenesis of Hemolytic Anemia

 



1. Hemolytic anemia is a type of anemia caused by premature destruction of red blood cells (RBCs), resulting in a shortened RBC lifespan.

2. Hemolysis may occur either intravascularly (within blood vessels) or extravascularly (mainly in the spleen and liver).

3. Hemolytic anemia may be classified as hereditary (e.g., thalassemia, sickle cell anemia, hereditary spherocytosis) or acquired (e.g., autoimmune hemolytic anemia, malaria, and drug-induced hemolysis).

4. Increased RBC destruction stimulates the bone marrow, resulting in reticulocytosis as a compensatory response.

5. Laboratory findings typically include decreased serum haptoglobin, increased unconjugated bilirubin, increased LDH, and increased reticulocyte count.

6. Peripheral blood film may show spherocytes, schistocytes, or other abnormal RBC shapes, depending on the underlying cause.

7. Clinical features include pallor, fatigue, jaundice, dark urine (particularly in intravascular hemolysis), and splenomegaly.

8. Treatment depends on the underlying cause and may include folic acid supplementation, corticosteroids for autoimmune hemolysis, blood transfusion when indicated, or splenectomy in selected cases.

Important point: The classical laboratory triad of hemolytic anemia is increased unconjugated bilirubin, increased LDH, and decreased serum haptoglobin.


0 Comments